FabiSpray will be used to treat adult patients with COVID-19 in partnership with SaNOtize
Glenmark Pharmaceuticals and Canadian pharmaceutical company SaNOtize Research & Development Corp announced the launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India; for the treatment of adult patients with COVID-19 who have a high risk of progression of the disease.
Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for NONS as part of the accelerated approval process.
Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.
